Hengrui Pharmaceutical announced that Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, recently received a notice from the State Drug Administration to approve the marketing of a Class 1 new drug, rikoncopam fumarate capsules, developed independently by the company to treat adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.